An overview of Polycystic Ovary Syndrome (PCOS)

With as many as 1 in 10 women living with Polycystic Ovary Syndrome (PCOS), many women still lack awareness of this relatively common condition and its symptoms. Affecting women of child-bearing age, PCOS symptoms can include excessive hair growth on the body or face as well as infrequent menstrual cycles. If you have been diagnosed, or have symptoms common to those of PCOS, keep reading! What is PCOS? Although the exact cause is unknown, physicians believe PCOS, a … Read more

Migraines: More Than a Headache

Migraines are estimated to affect 144 million men, women, and children worldwide. However, fewer than 5% have been seen by a healthcare provider, received an accurate diagnosis, and obtained the proper care. Seattle Women’s hopes to educate those who suffer from migraines by providing more information about when it is time to seek help. What … Read more

endometriosis Seattle Women’s: Health, Research, Gynecology

Understanding Endometriosis

​Endometriosis is a pain…literally.​The condition causes tissue that normally lines the inside of the uterus to grow outside your uterus. The tissue builds up with your menstrual cycle and sheds. IWith Endometriosis the tissue cannot shed normally, and can cause internal bleeding and scarring, leading to  pain and potential fertility issues.   Other symptoms can include painful … Read more

TherapeuticsMD Announces FDA Approval BIJUVA for Moderate to Severe Hot Flashes Due to Menopause

The FDA has just approved BIJUVA, an oral hormone therapy for moderate to severe vasomotor symptoms (also known as hot flashes) due to menopause. This is the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single capsule.​Menopause is a naturally occurring transition for women with an average onset age … Read more

AJOVY FDA Approved for the Preventative Treatment of Migraines and is Now Available in Pharmacies

On September 14, 2018 the FDA approved AJOVY (fremanezumab-vfrm) injection for the preventative treatment of migraines in adults. The medication is an injectable calcitonin-gene-related peptide (CGRP) antagonist. This is the second anti-CGRP treatment that has recently been approved. This treatment is available in both quarterly and monthly injections. AJOVY can be self-administered or administered in … Read more

FDA Approves Qbrexza Cloth for the Treatment of Hyperhidrosis

Seattle Women’s is pleased to announce that the FDA has approved a new treatment for axillary hyperhidrosis, also known as excessive underarm sweating. This is a chronic skin condition that affects approximately 10 million people in the United States and causes people to sweat more than what is necessary for normal thermal regulation. The approved … Read more

FDA Approves New Migraine Medication

Seattle Women’s is excited to announce that the FDA has approved Aimovig, a new treatment developed specifically for migraine headache prevention. Migraine is a debilitating condition that impacts 38 million patients in the United States. Seattle Women’s conducted one of the pivotal clinical trials involved in the approval process. Aimovig is the first medication in … Read more

Intrarosa for Postmenopausal Women Experiencing Pain During Sex Now Available in Pharmacies

Intrarosa (prasterone) was recently FDA approved to treat moderate to severe painful sexual intercourse (dyspareunia) caused by vulvar and vaginal atrophy (VVA). VVA is a common condition affecting up to 50% of postmenopausal women that results from the loss of estrogen during menopause. This causes the walls of the vagina and surrounding tissues to become … Read more

FDA Approves Elagolix (Orilissa) for Endometriosis Pain

On July 24th, 2018 the US Food and Drug Administration (FDA) approved Elagolix for the treatment of moderate to severe pain associated with endometriosis. Dr. Robin Kroll, director of Seattle Women’s Health Research Gynecology has conducted over a dozen clinical trials with the newly approved endometriosis treatment, Orilissa. The drug, Elagolix — now marketed as … Read more